where we learn about the disease, when to suspect and how to work up! The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several ...

The Pulmonary Vascular Research Institute (PVRI) is an independent medical research organization devoted to increasing the awareness and knowledge of pulmonary vascular diseases, and to facilitating ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

Heart failure related to PAH is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue.

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) 74th Annual Scientific Session and Expo in Chicago, March 29-31.

The new drug sotatercept stops the remodelling of the pulmonary vessels and even helps patients with advanced pulmonary arterial hypertension (PAH) who have not yet been treated.

"It was a pretty broad label, but this severity of disease had not been studied before," she said. "This is really broadening the scope of patients across the spectrum of pulmonary arterial ...

The Donald Heath pulmonary hypertension (PH) research vision and strategy is built on the foundations of the Sheffield Pulmonary Vascular Disease Unit (SPVDU) at the Royal Hallamshire, the UK’s ...